Invivyd to Present at 2024 ASCO and ATC Annual Meetings

Invivyd, Inc., a biopharmaceutical company listed on Nasdaq under the ticker IVVD, is focused on providing protection against severe viral infectious diseases. On May 29, 2024, the company announced plans to present preliminary subset analyses from its CANOPY Phase 3 clinical trial of VYD222, also known as pemivibart, for the pre-exposure prophylaxis of COVID-19. The findings will be shared at two significant upcoming medical conferences: the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting and the 2024 American Transplant Congress (ATC).

The ASCO Annual Meeting will be held from May 31 to June 4 in Chicago, IL. Invivyd's presentation, listed under Abstract #2532, will focus on the efficacy and safety of VYD222, an IgG1 monoclonal antibody, in preventing COVID-19. The subset analysis will highlight data from participants with significant immune compromise due to solid tumors or hematologic malignancies. Attendees can view the poster on Board #11 in Hall A on Saturday, June 1, from 9:00 AM to 12:00 PM CDT.

The ATC will take place from June 1 to June 5 in Philadelphia, PA. Invivyd will present preliminary results from solid organ transplant patients who participated in the CANOPY Phase 3 study under Abstract #A018. This presentation will also cover the efficacy and safety of VYD222 for COVID-19 prevention. The poster session is scheduled for Saturday, June 1, from 5:30 PM to 7:00 PM EST in the Poster Hall, Exhibit Hall A on Level 2.

Once these presentations have been made at the respective conferences, copies of the posters will be available on the Invivyd website under the 'Scientific Publications' section.

Invivyd, Inc. is dedicated to combating serious viral infectious diseases, starting with SARS-CoV-2, through its INVYMAB™ platform. This advanced platform integrates state-of-the-art viral surveillance and predictive modeling with sophisticated antibody engineering. INVYMAB is designed to enable the rapid and continuous development of new monoclonal antibodies (mAbs) to address evolving viral threats. In March 2024, Invivyd achieved a significant milestone when it received emergency use authorization (EUA) from the U.S. FDA for its first monoclonal antibody in a planned series of innovative candidates.

Invivyd's commitment to addressing viral diseases is reflected in its ongoing efforts to generate effective therapeutic solutions swiftly, ensuring preparedness for emerging viral threats. The company's participation in prestigious medical conferences like ASCO and ATC underscores its dedication to advancing scientific understanding and clinical practice in the field of infectious disease prevention.

In summary, Invivyd, Inc. is set to present crucial data from its CANOPY Phase 3 trial of VYD222 at two upcoming medical conferences. These presentations will provide valuable insights into the efficacy and safety of this monoclonal antibody in preventing COVID-19 among highly vulnerable patient groups, including those with significant immune compromise and solid organ transplant patients. The findings are anticipated to enhance the scientific community's knowledge and inform clinical practices aimed at protecting high-risk populations from COVID-19.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!